Author: "Marr, Helen" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Marr, Helen"' showing total 158 results

Start Over Author "Marr, Helen"

158 results on '"Marr, Helen"'

1. Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Author: Estcourt, Lise J, McQuilten, Zoe K, Bardy, Peter, Cole-Sinclair, Merrole, Collins, Graham P., Crispin, Philip J., Curnow, Elinor, Curnow, Jennifer, Degelia, Amber, Dyer, Claire, Friebe, Adam, Floro, Lajos, Grand, Effie, Hudson, Cara, Jones, Gail, Joseph, Joanne, Kallmeyer, Charlotte, Karakantza, Marina, Kerr, Paul, Last, Sara, Lobo-Clarke, Maria, Lumley, Matthew, McMullin, Mary F, Medd, Patrick G., Morton, Suzy M., Mumford, Andrew D., Mushkbar, Maria, Parsons, Joseph, Powter, Gillian, Sekhar, Mallika, Smith, Laura, Soutar, Richard, Stevenson, William S., Subramoniapillai, Elango, Szer, Jeff, Thomas, Helen, Waters, Neil A., Wei, Andrew H., Westerman, David A., Wexler, Sarah A., Wood, Erica M., Stanworth, Simon J., Abioye, Adrienne, Afghan, Rabia, Ai, Sylvia Ai, Akanni, Magbor, Alajangi, Rajesh, Alam, Usmaan, Al-Bubseeree, Bahaa, Alderson, Sophie, Alderson, Craig, Ali, Sayed, Ali, Kabir, Alighan, Rookmeen, Allam, Rebecca Allam, Allen, Tania, Al-Sakkaf, Wesam, Ames, Kate, Anderson, Jacqueline, Andrews, Colin, Angel, Ann-Marie, Anlya, Manuela Anlya, Ansari, Farah, Appleby, Rowan, Arnold, Claire, Asbjornsdottir, Hulda, Asfaw, Biruk, Atkins, Elissa, Atkinson, Leela, Aubrey, Clare, Ayesha, Noor, Babbola, Lola, Badcock, David, Badcock, Samuel, Baggio, Diva, Bailiff, Ben, Baines, Kizzy, Baker, Holly, Baker, Victoria, Ball, Lindsay, Ball, Martin, Balquin, Irwin, Banks, Emma, Banos, George, Barnett, Jaytee, Barrie, Claire, Barron, Claire, Barton, Rebecca, Bason, Nina, Batta, Bindu, Bautista, Dianne, Bayley, Angela, Bayly, Emma, Baynes, Fionnuala, Bazargan, Ali, Bazeley, Rachel, Beadle, Yvonne, Beardsmore, Claire, Beattie, Kate, Bedford, Caroline, Behal, Rachna, Behan, Daniel, Bejan, Lilihna, Bell, Sarah, Bell, Karen, Bell, Louise, Bell, Kaitlyn, Benjamin, Reuben, Bennett, Sam, Benson, Gary, Benson, Warwick, Bent, Cameron, Bergin, Krystal, Berry, Alex, Besenyei, Stephanie, Besley, Caroline, Betteridge, Scott, Beveridge, Leigh, Bhattacharyya, Abir, Billen, Annelies, Bilmon, Ian, Binns, Emma, Birt, Mark, Bishop, David, Blanco, Andrea, Bleby, Lisa, Blemnerhet, Richard, Blombery, Piers, Blyth, Emily, Blythe, Nicola, Boal, Lauren, Boden, Ali, Bokhari, Syed W.I., Bongetti, Elisa, Booth, Stephen, Borley, Jayne, Bowen, David, Bowers, Dawn, Boyd, Stephen, Bradley, Sarah, Bradman, Helen, Bretag, Peta, Brillante, Maria, Brockbank, Rachel, Brough, Yasmin, Brown, Ellen, Brown, Jo, Brown, Eleanor, Brown, Claire, Brown, Jenny, Brown, Susan, Browning, Joe, Brownsdon, Alex, Bruce, David, Brydon-Hill, Ruth, Buckwell, Andrea, Burgess, Dannielle, Burke, Glenda, Burley, Kate, Burney, Claire, Burns, David, Burrows, Samuel, burton, Kieran, Butler, Jason, Cambalova, Lenka, Camozzi, Maria C., Campbell, Philip, Campfield, Karen, Campion, Victoria, Cargo, Catherine, Carmona, Julia, Carney, Dennis, Casan, Joshua, Cashman, Helen, Catt, Lorraine, Cattell, Michael, Cavill, Megan, Chadbone, Rachel, Chaganti, Sridhar, Chai, Yee, Chai, Khai Li, Chang, Joshua, Chapman, Judith, Chapman, Oliver G., Chapter, Tamika, Charlton, Andrew, Chau, Celina, Chauhan, Saleena, Chavda, Nikesh, Chen, Frederick, Chen, Melody, Chen, Meng Xi, Chen, Melanie, Chen, Melissa, Cheok, Kathleen, Cheung, Mai, Chidgey, Luke, Chmielokliec, Karolina, Choi, Philip, Choi, Jae, Chok, Anne, Chopra, Ruchika, Christopherson, Louise, Chu, Vicky, Chua, Chong Chyn, Chudakou, Pavel, Chugh, Vidushi, Chung, Chi, Clark, Erin, Clarke, Peter, Clarke, Kathleen, Clay, Jennifer, Clayton, Laura, Clements, Mitch, Clemmens, Jonathan, Clifford, Ruth, Collett, Dave, Collins, Maia, Collyer, Emily, Connolly, Maureen, Cook, Mark, Coombs, Sarah, Coppell, Jason, Cornwell, Sophie, Corrigan, Claire, Coughlin, Elizabeth, Couling, Jennifer, Cousins, Tony, Cowan, Catriona, Cox, Christine, Cox, Catherine, Coyle, Luke, Craig, Emily, Creasey, Thomas, Croan, Laura, Croft, Jane, Crosbie, Nicola, Crowe, Josephine, Crowther, Helen, Crozier, Jane, Culleton, Naomi, Cullis, Jonathan, Cumming, Anita, Cummins, Michelle, Cunningham, Adam, Curley, Cameron, Curtis, Samantha, Cuthbert, Robert, Cuthill, Kirsty, Dahahayake, Dinusha A, Dang, Amy, Davies, Marc, Davies, Ceri, Dawson, Emily, Day, Tom, De Abrew, Kanchana, De Lavallade, Hugues, De Silva, Neelaskshi, Dean, Georgina, Deane, Christopher, Demosthenous, Lisa, Desai, Amisha, Desborough, Michael, Devanny, Ian, Dhanapal, Jay, Dhani, Sundip, Di Martino, Vicky, Dickens, Emmy, DiCorleto, Carmen, Dinnett, Louise, Dirisan, Divya, Dixon, Karen, Dixon, Kiri, Doal, Inderjit, Dobivh, J, Docanto, Maria, Doecke, Helve, Donaldson, David, Donaldson, Kylee, Donohoe, Carrie, Douglas, Ashley, Doung, Stephen, Downer, Susan, D'Rozario, James, Drummond, Malcolm, Drummond, Mark, Drummond, Samantha, Drysdale, Elizabeth, D'Souza, Ross, D'Souza, Eugene, Dunn, Alex, Dutton, David, Dyson, Martin, Ediriwicurena, Kushani, Edleston, Sharon, Edwards, Dawn, Edwards, Morgan, Edwards, Anita, Eise, Nicole, Ellis, Steven, Ellis, Hayley, Elmonley, Shareef, Enstone, Rosemarie, Eordogh, Agnes, Erb, Sharon, Evans, Shannon, Evans, Megan, Ewing, Joanne, Eyre, Toby, Facey, Adam, Fammy, Mina, Farman, Jon, Farnell, Rachel, Favero, Laura, Fay, Keith, Ferguson, Karen, Fernon, Laura, Filshie, Robin, Finnegan, Damian, Fisher, Lisa, Flanagan, Asia, Fleck, Emma, Fletcher, Simon, Flora, Harpreet, Flower, Catherine, Fodor, Ioana, Foley, Heather, Folland, Emma, Folorunso, Comfort, Forbes, Molly, Fordwor, Katrina, Foster, Polly, Fox, Vanessa, Fox, Thomas, Francis, Olesya, Fryearson, Louise, Fuery, Madonna, Fung, Jiin, Furtado, Michelle, Galloway-Browne, Leanne, Gamble, Louise, Gamgee, Jeanette, Ganapathy, Arundathi, Gardner, Hayley, Gardner, Clare, Gasmelsheed, Noha, Gately, Amy, Gaynor, Lynda, Gebreid, Alex, Geffens, Ruth, George, Rachel, Gertner, Aniko, Ghebeh, Manar, Ghirardini, Emanuela, Giddings, Melainie, Gillett, Sandra, Gillett, Karen, Giri, Pratyush, Glass, Chris, Glewis, Sarah, Gooding, Sarah, Gordon, Olivia, Gordon, Joanne, Gottlieb, David, Gowda, Koushik, Gower, Elysie, Gray, Nicola, Grayer, Jo, Greaves, Elaine, Greenaway, Sally Anne, Greenfield, Graeme, Greenwood, Matthew, Gregory, Gareth, Griffin, James, Griffith, Julia, Griffith, James, Griffiths, Lindsey, Grzegrzolka, Paulina, Gu, Yisu, Guest, Jo, Guinai, Rosanna, Gullapalli, Veena, Gunolr, A., Guo, Lina, H, Wayne, Hagua, Sophia, Haile, Senait, Hall, Richard, Hamdollah-Zadeh, Maryam, Hanif, Zahra, Hanlon, Kathleen, Hann, Nicholas, Hanna, Ramez, Hannah, Guy, Hapuarachchi, Sameera, Hardman, Jacinta, Hardy, Alison, Harris, Anthony, Harris, Kylie, Harrison, Beth, Harrison, Simon, Harrison, Lea-Anne, Harrop, Sean, Harvey, Caroline, Hatcliffe, Faye, Hawking, Jo, Hawkins, Matthew, Hayden, Janet, Hayman, Michelle, Haynes, Elizabeth, Heaney, Nicholas, Hebbard, Andrew, Hempton, Jenny, Hendunneti, Sasanka, Henry, Maeve, Heywood, Jonathan, Hildyard, Catherine, Hill, Lydia, Hilldrith, Annette, Hitev, Petar, Hiwase, Smita, Hiwase, Devendra, Hoare, Chris, Hodge, Renate, Holloway, Amy, Holt, Chloe, Holton, Kelly, Homer, Lauren, Horne, Gillian, Horvath, Noemi, Hotong, Linda, Houdyk, Kristen, Houseman, Katy, Hoxhallari, Ilda, Hsu, Hannah, Hsu, Nina, Huang, Gillian, Hudson, Kerryn, Hufton, Melanie, Hughes, Timothy, Hughes, Siobhan, Hurley, Kate, Huxley, Rosie, Ibitoye, Temitope, Ibrouf, Abubaken, Inam, Farha, Indran, Tishya, Ingham, Karen, Innes, Calum, Irvine, David, Jaafar, Sarah, Jain, Manish, Jameson, Laura, Janjua, Pardeep, Jarvis, Rebecca, Jatheendran, Abirami, Javed, Abbie, Jen, Sheila, Jobanpura, Shailesh, Jobson, Irene, John, Deborah, Johns, Sophie, Johnston, Amanda, Jones, Hollie, Jones, Francesca, Joniak, Karolina, Jovanovic, Michael, Jovic, Anita, Joyce, Lauren, Judd, Andrew, Kakarlamudi, Sudhakar, Kakaroubas, Nick, Kalita, Maggie, Kam, Shirly, Kan, Julie, Kandle, P, Kanellopoulos, Alex, Kao, Chien, Kaparou, Maria, Kartsios, Charamlampos, Katsioulas, Vicki, Kaye, Russell, Keen, Katie, Kelly, Richard, Kelly, Pauline, Kelly, Donna, Kelly, Melanie, Kennedy, Glen, Kennedy, Nola, Kenny, Angela, Kenworthy, Zoe, Kerridge, Ian, Kesavan, Murali, Khafizi, Angelika, Khakwani, Muhammad, Khalid, Amna, Khamly, Kate, Khan, Anjum, Khan, Dalia, Khan, Mojid, Khan, Lubna, Khoo, Mona, Khwaja, Asim, Kim, Grace, King, Andrew, King, Vicky, King, Donna, Kinsella, Francesca, Kipp, David, Kirandeep, Pachoo, Kirui, Laura C., Kishore, Bhuvan, Knectlhi, Christopher, Knot, Amy, Knot, Armit, Ko, Cathy, Kolaric, Caitlin, Koo, Ray, Kotadia, Mary, Kothari, Jaimal, Kottaridis, Panagiotis D., Kuiluinathan, Gajan, Kulasekararaj, Austin, Kwan, John, Kwok, Marwan, Kwok, Phillip, Kwok, Fiona, Laane, Kristiina, Lad, Deena, Laird, Jennifer, Lam, Ada, Lane, Mary, Lanenco, Monica, Lang, Susan, Langridge, Alex, Langton, Catherine, Lannon, Michelle, Latif, Annie, Latimer, Maya, Latter, Ruth, Lau, I-Jun, Lawless, Sarah, Lawless, Theresa, Leach, Mike, Leaney, Sarah, Leary, Heather, Leavy, James, LeBlanc, Abbey, Lee, Vivienne, Lee, Edwin, Lee, Jenny, Lee, Tamara, Leischkie, Marian, Leitinger, Emma, Leon, Christopher, Leonard, Jayne, Lewis, David, Lewis, Ian, Lewis, Tania, Lim, Daniel, Littlewood, Kelly, Liu, Dara, Loh, Joanna, Lokare, Anand, Lomas, Oliver, Lovell, Richard, Lowe, Theresa, Lowry, Lisa, Lubowiecki, Marcin, Lumb, Rebecca, Lynch, Gail, Macaulay, Amanda, MacDonald, Lyndsey, MacDonald-Burn, Jill, Macmillan, Margaret, Maddock, Karen, Mahaliyana, Tomas, Mahon, Cassandra, Maidment, Alison, Maier, Susie, Mairos, Michelle, Majid, Mahseeman, Mak, Ka L, Mak, Anne, Malendrayogau, Arunthrthy, Malham, Hana, Malyon, Felicity, Mandadapu, Vineela, Mandel, Laura, Mant, Sarah, Manton, Ruth, Maouche, Nadjoua, Maqbool, Muhammad G., Marchant, Gregory, Marinho, Mariana, Marks, David, Marner, Mike, Marr, Helen, Marshall, Gillian, Martin, Siobhan, Martin, Abigail, Marzolini, Maria, Mason, Kiara, Massie, Jonathan, Masson, Rebecca, Mathavan, Vidya, Mathew, Siju, Mathie, Judith, Mattocks, Lehenta, Maybury, Bernard, Mayer, Georgina, McAlister, Chyrelle, McAllister, Jo, McConnell, Stewart, McCracken, James, McCullagh, Liz, McCulloch, Rory, Mcdermott, Christopher, Mcdonald, Kerian, McGinniss, Laura, McGurk, Fiona, McIlwain, Jessica, McIver, Kirsten, Mckay, Pam, McKenna, Lorraine, Mclornan, Donal, McMahon, Coalon, McNeice, Linda, McNeill, Susan, McNickle, Molly, McQueen, Fiona, McRae, Simon, McTaggart, Bobby, Mehew, Jenny, Mehra, Varnn, Melly, Michelle, Menichelli, Tara, Micklethwatte, Ken, Mihailescue, Loredana, Mijovic, Aleksander, Millband, Hannah, Miller, Lucy, Millien, Samuel T., Milnthorpe, James, Minson, Adrian, Molnar, Eva, Monsour, Marc, Moody, Mary, Moon, Rebecca, Moore, Sally, Moore, Katy, Morgan, Kelly, Morralley, Rebecca, Morris, Denise, Morris, Kirk, Morrison, Nicole, Moss, Merinda, Mughal, Muhammad, Muir, Paul, Mukkath, David, Mulla, Aasiyu, Mulligan, Stephen, Mullings, Joanne, Mulqueen, Angela, Muluey, Caitlin, Murdoch, Sarah, Murrani, Sura, Murthy, Vidhya, Musngi, Jimmy, Mustafa, Nadreen, Mynes, Tracey, Nalpantidis, Anastasios, Nandurkar, Harshal, Nardone, Linda, Nasari, Latifa, Nash, Monica, Naylor, Georgina, Ngu, Loretta, Nguethina, Melissa, Nguyen, John, Nguyen, Joseph, Nichol, Wendy, Nicholls, Emma, Nicole, Catherine S., Nicolson, Phillip, Nielson, David, Nikolousis, Emmanouil, Nix, Georgina, Njoku, Rita, Norman, Jane, Norman, Amy, Norris, Phoebe, North, Daniel, Norwood, Megan, Notcheva, Gaynor, Novitzky-Basso, Igor, Nyaboko, Joseph, Nygren, Maria, Obu, Ingrid, O'Connell, Siobhan, O'Connor, Jody, O'Kelly, Deanna, O'Niell, Aideen, Ony, Jeremy, Oo, Kathy, Oo, April, Oppermann, Anne, Orr, Ruth, O'Sullivan, Mary, Page, Jennifer, Palfreyman, Emma, Paneesha, Shankaranarayana, Panicker, Shyam, Parbutt, Catherine, Parigi, Elesha, Paris, Gemma, Parker, Tracey, Parnell, Caroline, Parrish, Christopher, Parsons, Alex, Pasat, Mioara, Patel, Natasha, Patel, Vijay, Patel, Pooja, Patel, Chaya, Pati, Nalini, Patterson, Andrea, Paul, Lauren, Payet, Danielle, Payne, Elspeth, Peachey, Victoria, Pearson, Amanda, Peniket, Andy, Percy, Laura, Pereyra, Millicent, Pervaiz, Omer, Phalod, Gunjan D, Pham, Anh, Pho, Jason, Pickard, Keir, Pidcock, Michael, Piggin, Anna, Pishyar, Yalda, Pocock, Abigail, Pol, Ranjendres, Polzella, Paolo, Poolan, Sonia, Portingale, Vicki, Posnett, Claire, Potluri, Sandeep, Potter, Victoria, Pratt, Guy, Prodger, Catherine, Pueblo, Andres, Puliyayil, Anish, Puvanakumar, Pratheepan, Qadri, Abdul, Quach, Hang, Quinn, Michael, Rafferty, Mark, Rahman, Marzia, Raj, Kavita, Raj, Sonia, Rajendran, Ramina, Ramanan, Radha, Ramasamy, Karthik, Rampotas, Alexandros, Ranchhod, Natasha, Rashid, Sabia, Ratanjee, Sunita, Rathore, Gurpreet, Ratnasingam, Sumita, Rayat, Manjit, Rayner, Michael, Reddell-Denton, Rebecca, Redding, Nicola, Reddy, Udaya, Rehman, Atique, Rice, Carol, Riches, Iwona, Rider, Thomas, Riley, John, Rinaldi, Ciro, Roberts, Kayleigh, Roberts, Andrew, Robertson, Bryony, Robertson, Peter, Robinson, Dan, Robinson, Rebecca, Robjohns, Emma, Robledo, Laura, Rodrigues, Ana, Rofe, Chris, Roff, Bridie, Rogers, Rachel, Rolt, Jill, Rooney, Carmela, Rose, Kathy, Rose, Hannah, Ross, David, Rouf, Shahara, Rourke, Claire, Routledge, David, Ruggiero, Janet, Rule, Simon, Rumsey, Richard, Sagge, Cherry, Saldhana, Helen, Salisbury, Richard, Salisbury, Sarah, Salvaris, Ross, Sanders, Kay, Sangombe, Mirriam, Sanigorska, Anna, Santos, Kristine, Sarkis, Taylah, Sarma, Anita, Saunders, Natalie, Schmidt, Kara, Schmidtmann, Anja, Schumacher, Ann, Scorer, Tom Scorer, Scott, Asleigh, Seath, Ingrid, Sejman, Frances, Selim, Adrian, Shamim, Nadia, Shan, Jocelyn, Shanmuganathan, Naranie, Shanmugaranjan, Shaminie, Sharpe, Michelle, Sharpley, Faye, Shaw, Emma, Sheath, Cara, Sheehy, Oonagh, Shen, Vivian, Sherbide, Solomon, Sheridan, Mathew, Sheridan, Jane, Sheridon, Matthew, Shields, Tracy, Sim, Hau V, Sim, Shirlene, Sims, Matt, Singaraveloo, Lydia, Singh, Gurcharan, Singh, Jasmine, Sladesal, Shree, Sloan, Andrew, Slobodian, Peter, Smith, Sophie, Smith, Sarit, Smith, Claire, Smith, Alastair, Smith, Neil, Snowden, Katherine, Solis, Joel, Somios, Denise, Soo, Jade, Spanevello, Michelle, Spaulding, Madeleie, Spence, Laura, Spillane, Liz, Spiteri, Alisha, Sprigg, Naomi, Springett, Sally, Stafford, Lynn, Stainthorp, Katherine, Stark, Kate, Steeden, Louise, Stephen, Ella, Stephenson, Aisling, Stewart, Andrew, Stewart, Orla, Stobie, Emma, Stokes, Chelsea, Streater, Jacqui, Suddens, Charlie-Marie, Suntharalingam, Surenthini, Surana, Narinder, Sutherland, Robyn, Sutherland, Antony, Sutton, David, Sweeney, Connor, Sweet, Reilly, Szucs, Aniko P, Taheri, Leila E., Tailor, Hinesh, Tam, Constantine, Tambakis, George, Tamplin, Mary, Tan, Chee, Tan, Sui, Tan, Joanne, Tan, Zhi, Taran, Tatiana, Tarpey, Fiona, Taseka, Angela, Tasker, Suzy, Tatarczuch, Maciej, Tayabali, Sarrah, Taylor, Hannah, Taylor, Robert, Taylor, Melaine, Taylor-Moore, Ella, Teasdale, Lesley, Tebbet, Elizabeth, Tedjasepstra, Aditya, Tedjaseputra, Aditya, Tepkumkun, Oummy, Terpstra, Andrew, Thomas, Wayne, Thomas, Shanice, Thompson, Rachel, Thornton, Thomas, Thorp, Bronwyn, Thrift, Moi Yap, Thwaites, Phillipa, Timbres, Jasmine, Tindall, Lauren, Tiong, Ing Soo, Tippler, Nicole, Todd, Tony, Todd, Shirley, Toghill, Neil, Tomlinson, Eve, Tooth, Jacinta, Topp, M., Trail, Nicola, Tran, Nguyen, Tran, Elizabeth, Tran, Vi, Treder, Bona, Tribbeck, Michelle, Trochowski, Siobhan, Truslove, Maria, Tse, Tsun, Tseu, Bing, Tucker, David, Turner, Kelly, Turner, Dianne, Turner, Herleen, Turner, Gillian, Twohig, Julie, Tylee, Thomas, Uhe, Micheleine, Underhill, Lauren, V, Joanne, Van der Vliet, Georgina, Van Tonder, Tina, VanderWeyden, Carrie, Varghese, Jerry, Vaughan, Lachlan, Veale, David, Vickaryyous, Nicky, Vince, Kathryn, Von Welligh, Jacoba, Vora, Sona, Wadehra, Karan, Walker, Rebecca, Walker, Stephen, Wallace, Roslyn, Wallniosve, Stephanie, Wallwork, S., Walmsley, Zoe, Walters, Fiona, Wang, Joyce, Wang, Angela, Wang, Chen, Wanyika, Mercy, Warcel, Dana, Wardrobe, Katrina, Warnes, Kristian, Waterhouse, Christopher, Waterworth, Adam, Watson, Caroline, Watson, Edmund, Watts, Emily, Weaver, Emma, Weber, Nicholas, Webley, Kaytie, Welford, Anna, Wells, Matt, Westbury, Sarah, Westcott, Jackie, Western, Robyn, Weston, Julia, White, Jessica, White, Phillipa, Whitehead, Anna, Whitehouse, James, Wieringa, Samantha, Willan, John, Williams, Sandra, Williams, Bethany, Williamson, Stephanie, Willoughby, Brett, Wilmot, Gail, Wilmott, Rosalind, Wilson, Joanna, Wilson, Emma, Wilson, Suzy, Wilson, Heather, Wilson, Caroline, Wilson, Tanya, Wilton, Margaret, Wiltshire, Paula, Wincup, Joanne, Wolf, Julia, Wong, Henna, Wong, Cyndi, Wong, Daniel, Wong, Jonathan, Wong, Shi Qin, Wood, Sarah, Wood, Henry, Wooding, Jackie, Woolley, Kelly, Wright, Myles, Wynn-Williams, Roland, Yannakou, Costas, Yeoh, Zhi Han, Yeung, David, Young, Agnes, Yuen, Flora, Yuen, Agnes, Zaja, Oliver, Zhang, Xiao-Yin, and Zhang, Mei
Published: 2025
Full Text: View/download PDF

2. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia

Author: Stölzel, Friedrich, Fordham, Sarah E, Nandana, Devi, Lin, Wei-Yu, Blair, Helen J, Elstob, Claire J, Bell, Hayden L, Mohr, Brigitte, Ruhnke, Leo, Kunadt, Desiree, Dill, Claudia, Allsop, Daniel A, Piddock, Rachel E, Soura, Emmanouela-Niki, Park, Catherine Vida, Fadly, Mohd, Rahman, Thahira, Alharbi, Abrar A, Wobus, Manja, Altmann, Heidi, Röllig, Christoph, Wagenführ, Lisa, Jones, Gail L, Menne, Tobias, Jackson, Graham H, Marr, Helen J, Fitzgibbon, Jude, Onel, Kenan, Meggendorfer, Manja, Robinson, Amber, Bziuk, Zuzanna, Bowes, Emily, Heidenreich, Olaf, Haferlach, Torsten, Villar, Sara, Ariceta, Beñat, Diaz, Rosa Ayala, Altschuler, Steven J, Wu, Lani, Prosper, Felipe, Montesinos, Pau, Martinez-Lopez, Joaquin, Bornhäuser, Martin, and Allan, James M
Subjects: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Hematology, Genetics, Pediatric, Pediatric Cancer, Rare Diseases, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Humans, Mice, Animals, Azacitidine, Leukemia, Myeloid, Acute, Kaplan-Meier Estimate, Mutation, DNA-Binding Proteins, Dioxygenases, Leukemias, Molecular genetics, Biomedical and clinical sciences, Health sciences
Abstract: Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations in an elderly patient with acute myeloid leukemia (AML) that was chemoresistant to anthracycline and cytarabine but acutely sensitive to 5'-azacitidine (5'-Aza) hypomethylating monotherapy, resulting in long-term morphological remission. Given the role of TET2 as a regulator of genomic methylation, we hypothesized that mutant TET2 allele dosage affects response to 5'-Aza. Using an isogenic cell model system and an orthotopic mouse xenograft, we demonstrate that biallelic TET2 mutations confer sensitivity to 5'-Aza compared with cells with monoallelic mutations. Our data argue in favor of using hypomethylating agents for chemoresistant disease or as first-line therapy in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of precision medicine for patients with cancer.
Published: 2023

3. Successful treatment of transplant-associated microangiopathy with rituximab

Author: Marr, Helen, (and others)
Published: 2009

4. Containment management : a fresh approach to working with the agricultural sector

Author: Marr, Helen
Published: 2007

5. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study

Author: Tivey, Ann, Shotton, Rohan, Eyre, Toby A., Lewis, David, Stanton, Louise, Allchin, Rebecca, Walter, Harriet, Miall, Fiona, Zhao, Rui, Santarsieri, Anna, McCulloch, Rory, Bishton, Mark, Beech, Amy, Willimott, Victoria, Fowler, Nicole, Bedford, Claudia, Goddard, Jack, Protheroe, Sam, Everden, Angharad, Tucker, David, Wright, Josh, Dukka, Vasavi, Reeve, Miriam, Paneesha, Shankara, Prahladan, Mahesh, Hodson, Andrew, Qureshi, Iman, Koppana, Manasvi, Owen, Mary, Ediriwickrema, Kushani, Marr, Helen, Wilson, Jamie, Lambert, Jonathan, Wrench, David, Burney, Claire, Knott, Chloe, Talbot, Georgina, Gibb, Adam, Lord, Angela, Jackson, Barry, Stern, Simon, Sutton, Taylor, Webb, Amy, Wilson, Marketa, Thomas, Nicky, Norman, Jane, Davies, Elizabeth, Lowry, Lisa, Maddox, Jamie, Phillips, Neil, Crosbie, Nicola, Flont, Marcin, Nga, Emma, Virchis, Andres, Camacho, Raisa Guerrero, Swe, Wunna, Pillai, Arvind, Rees, Clare, Bailey, James, Jones, Steve, Smith, Susan, Sharpley, Faye, Hildyard, Catherine, Mohamedbhai, Sajir, Nicholson, Toby, Moule, Simon, Chaturvedi, Anshuman, and Linton, Kim
Published: 2024
Full Text: View/download PDF

6. Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia.

Author: Aptullahoglu, Erhan, Howladar, Mohammed, Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Irving, Julie, Willmore, Elaine, and Lunec, John
Subjects: CHRONIC lymphocytic leukemia, T-test (Statistics), ANTINEOPLASTIC agents, APOPTOSIS, TREATMENT effectiveness, DESCRIPTIVE statistics, CELL lines, DRUG interactions, ONCOGENES, CELL survival, GENETIC mutation, DATA analysis software, IMMUNOBLOTTING
Abstract: Simple Summary: This study explores HDM201, a second-generation MDM2-p53 binding antagonist, as a potential novel treatment for chronic lymphocytic leukemia (CLL). Using a range of B cell lines and primary CLL samples with different TP53 statuses, we found that HDM201 effectively targets TP53 wild-type and heterozygous TP53-KO cells but shows limited efficacy in TP53 mutant and homozygous TP53-KO cells. HDM201 stabilizes p53 and induces apoptosis in sensitive cells, demonstrating its potential as a targeted therapy for TP53 wild-type CLL cases. This study highlights the importance of TP53 status in predicting treatment response and suggests further research on resistance mechanisms and combination therapies. Background: Chronic lymphocytic leukemia (CLL) treatment has transitioned from traditional chemotherapy to more targeted therapies, but challenges such as resistance and suboptimal responses persist. This study aimed to evaluate HDM201, a second-generation MDM2-p53 binding antagonist, as a novel therapeutic strategy for CLL, with a focus on its effectiveness across different TP53 genetic contexts. Methods: We utilized a panel of B cell leukemia-derived cell lines with varying TP53 statuses, including TP53-knockout (KO) derivatives of the human B cell line Nalm-6, and assessed the impact of HDM201 on primary CLL samples with both TP53 wild-type and mutant backgrounds. Results: Our results revealed that TP53 wild-type and heterozygous TP53-KO Nalm-6 cells were sensitive to HDM201, whereas homozygous TP53-KO cells and B cells with TP53 mutations exhibited significant resistance. Resistance was also noted in primary CLL samples with TP53 mutations. HDM201 effectively stabilized p53 and induced apoptosis in TP53 wild-type cells but had limited efficacy in TP53 mutant cells. Conclusions: These findings indicate that HDM201 holds promise as an additional targeted therapy option for wild-type TP53 CLL. The results underline the importance of TP53 status in predicting treatment efficacy and highlight the potential of HDM201 as a valuable addition to explore in CLL therapy. Future research should focus on identifying additional biomarkers of response and exploring the optimal way to include HDM201 in combination therapies to improve treatment outcomes in CLL. [ABSTRACT FROM AUTHOR]
Published: 2025
Full Text: View/download PDF

7. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author: Lin, Wei-Yu, Fordham, Sarah E., Hungate, Eric, Sunter, Nicola J., Elstob, Claire, Xu, Yaobo, Park, Catherine, Quante, Anne, Strauch, Konstantin, Gieger, Christian, Skol, Andrew, Rahman, Thahira, Sucheston-Campbell, Lara, Wang, Junke, Hahn, Theresa, Clay-Gilmour, Alyssa I., Jones, Gail L., Marr, Helen J., Jackson, Graham H., Menne, Tobias, Collin, Mathew, Ivey, Adam, Hills, Robert K., Burnett, Alan K., Russell, Nigel H., Fitzgibbon, Jude, Larson, Richard A., Le Beau, Michelle M., Stock, Wendy, Heidenreich, Olaf, Alharbi, Abrar, Allsup, David J., Houlston, Richard S., Norden, Jean, Dickinson, Anne M., Douglas, Elisabeth, Lendrem, Clare, Daly, Ann K., Palm, Louise, Piechocki, Kim, Jeffries, Sally, Bornhäuser, Martin, Röllig, Christoph, Altmann, Heidi, Ruhnke, Leo, Kunadt, Desiree, Wagenführ, Lisa, Cordell, Heather J., Darlay, Rebecca, Andersen, Mette K., Fontana, Maria C., Martinelli, Giovanni, Marconi, Giovanni, Sanz, Miguel A., Cervera, José, Gómez-Seguí, Inés, Cluzeau, Thomas, Moreilhon, Chimène, Raynaud, Sophie, Sill, Heinz, Voso, Maria Teresa, Lo-Coco, Francesco, Dombret, Hervé, Cheok, Meyling, Preudhomme, Claude, Gale, Rosemary E., Linch, David, Gaal-Wesinger, Julia, Masszi, Andras, Nowak, Daniel, Hofmann, Wolf-Karsten, Gilkes, Amanda, Porkka, Kimmo, Milosevic Feenstra, Jelena D., Kralovics, Robert, Grimwade, David, Meggendorfer, Manja, Haferlach, Torsten, Krizsán, Szilvia, Bödör, Csaba, Stölzel, Friedrich, Onel, Kenan, and Allan, James M.
Published: 2022
Full Text: View/download PDF

8. Financial incentives for large-scale wetland restoration: Beyond markets to common asset trusts

Author: Canning, Adam D., Jarvis, Diane, Costanza, Robert, Hasan, Syezlin, Smart, James C.R., Finisdore, John, Lovelock, Catherine E., Greenhalgh, Suzie, Marr, Helen M., Beck, Michael W., Gillies, Christopher L., and Waltham, Nathan J.
Published: 2021
Full Text: View/download PDF

9. Regulation of CD38 by IRF4 in chronic lymphocytic leukemia

Author: Marr, Helen Judith
Subjects: 616.99
Abstract: Genome‐wide association analysis identified rs872071, a common variant in the 3’UTR of IRF4, as tagging a risk allele for chronic lymphocytic leukaemia (CLL). The risk allele is significantly associated with expression of CD38, a poor prognostic marker in CLL. IRF4 is a transcription factor with pleiotropic roles in the regulation of B cell development, and interrogation of the CD38 gene identified a number of putative binding sites for IRF4, suggesting that CD38 may be transcriptionally regulated by IRF4. Chromatin immunoprecipitation (ChIP) demonstrated significant IRF4‐CD38 binding at two composite ETS/IRF consensus element (EICE) sites in SU‐DHL‐6 and MEC‐1 mature B cell lines. Furthermore, there was evidence of IRF4‐CD38 binding at these EICE sites in primary CLL lymphocytes in some, but not all, cases. ChIP studies using markers of histone methylation suggested increased transcriptional activation at the IRF4‐CD38 binding sites in MEC‐1 cells with IRF4 knockdown. In contrast, transcriptional activity at these sites appeared to be reduced in SU‐DHL‐6 cells with IRF4 knockdown. Co‐culture of primary CLL lymphocytes on a CD40L‐expressing monolayer led to an upregulation of IRF4 expression, but no consistent effect on CD38 expression. In addition, ChIP studies using markers of histone methylation were suggestive of reduced transcriptional activity at the IRF4‐CD38 binding site after CD40L co‐culture, suggesting that IRF4 may be a negative regulator of CD38 in CLL. Taken together, the evidence indicates that IRF4 binds to the CD38 locus. However, direct experimental evidence for an effect on CD38 expression is lacking. It is necessary to consider that the interaction between IRF4 and CD38 is unlikely to be a linear signal transduction pathway. Indeed the prevailing evidence regarding the function of IRF4 in B cells suggests a complex signalling network involving numerous other transcription factors and cytokines. Furthermore, IRF4 has been suggested as a putative therapeutic target in haematological malignancies including myeloma. Transient IRF4 knockdown using RNA ii interference (RNAi) techniques was tolerated by SU‐DHL‐6, MEC‐1 and lymphoblastoid TK6 cell lines, though cell proliferation in TK6 and SU‐DHL‐6 was significantly impaired. Long‐term stable knockdown was also tolerated in TK6 cells, but not in MEC‐1 cells, suggesting an essential role for IRF4 in maintenance of MEC‐1 cells. Targeted knockdown of IRF4 also sensitised TK6 B cells and MEC‐1 CLL cells to the growth inhibitory effects of fludarabine, a nucleoside analogue used in the treatment of CLL. These findings indicate that IRF4 is necessary to the maintenance of MEC‐1 cells, which represent a CLL cell line model. A greater understanding of the role of IRF4 in the development and maintenance of CLL may indicate new therapeutic targets in CLL. Indeed, a recently developed novel mouse model of CLL has indicated that deficient IRF4 expression predisposes to the development of CLL. However, the role of IRF4 in the maintenance of CLL cells is yet to be determined. The heterogeneous nature of IRF4 expression in primary CLL lymphocytes determined here, and its potentially pleiotropic role in the transcriptional regulation of CD38 in B cells at different stages of differentiation, suggest that if IRF4 is a key player in the maintenance of the leukaemic clone, its role may be context or patient specific, and dependent on other signalling components or somatic genetic abnormalities.
Published: 2016

10. Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia

Author: Barrow, Timothy M., Nakjang, Sirintra, Lafta, Fadhel, Bilotkach, Kateryna, Woodhouse, Laura, Junge, Gesa, Tudhope, Susan J., Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, and Strathdee, Gordon
Published: 2021
Full Text: View/download PDF

11. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author: Lin, Wei-Yu, Fordham, Sarah E., Hungate, Eric, Sunter, Nicola J., Elstob, Claire, Xu, Yaobo, Park, Catherine, Quante, Anne, Strauch, Konstantin, Gieger, Christian, Skol, Andrew, Rahman, Thahira, Sucheston-Campbell, Lara, Wang, Junke, Hahn, Theresa, Clay-Gilmour, Alyssa I., Jones, Gail L., Marr, Helen J., Jackson, Graham H., Menne, Tobias, Collin, Mathew, Ivey, Adam, Hills, Robert K., Burnett, Alan K., Russell, Nigel H., Fitzgibbon, Jude, Larson, Richard A., Le Beau, Michelle M., Stock, Wendy, Heidenreich, Olaf, Alharbi, Abrar, Allsup, David J., Houlston, Richard S., Norden, Jean, Dickinson, Anne M., Douglas, Elisabeth, Lendrem, Clare, Daly, Ann K., Palm, Louise, Piechocki, Kim, Jeffries, Sally, Bornhäuser, Martin, Röllig, Christoph, Altmann, Heidi, Ruhnke, Leo, Kunadt, Desiree, Wagenführ, Lisa, Cordell, Heather J., Darlay, Rebecca, Andersen, Mette K., Fontana, Maria C., Martinelli, Giovanni, Marconi, Giovanni, Sanz, Miguel A., Cervera, José, Gómez-Seguí, Inés, Cluzeau, Thomas, Moreilhon, Chimène, Raynaud, Sophie, Sill, Heinz, Voso, Maria Teresa, Lo-Coco, Francesco, Dombret, Hervé, Cheok, Meyling, Preudhomme, Claude, Gale, Rosemary E., Linch, David, Gaal-Wesinger, Julia, Masszi, Andras, Nowak, Daniel, Hofmann, Wolf-Karsten, Gilkes, Amanda, Porkka, Kimmo, Milosevic Feenstra, Jelena D., Kralovics, Robert, Grimwade, David, Meggendorfer, Manja, Haferlach, Torsten, Krizsán, Szilvia, Bödör, Csaba, Stölzel, Friedrich, Onel, Kenan, and Allan, James M.
Published: 2021
Full Text: View/download PDF

12. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

Author: Taha, Yusri, Wardle, Hayley, Evans, Adam B., Hunter, Ewan R., Marr, Helen, Osborne, Wendy, Bashton, Matthew, Smith, Darren, Burton-Fanning, Shirelle, Schmid, Matthias L., and Duncan, Christopher J. A.
Published: 2021
Full Text: View/download PDF

13. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia

Author: Lin, Wei-Yu, Fordham, Sarah E., Sunter, Nicola, Elstob, Claire, Rahman, Thahira, Willmore, Elaine, Shepherd, Colin, Strathdee, Gordon, Mainou-Fowler, Tryfonia, Piddock, Rachel, Mearns, Hannah, Barrow, Timothy, Houlston, Richard S., Marr, Helen, Wallis, Jonathan, Summerfield, Geoffrey, Marshall, Scott, Pettitt, Andrew, Pepper, Christopher, Fegan, Christopher, Forconi, Francesco, Dyer, Martin J. S., Jayne, Sandrine, Sellors, April, Schuh, Anna, Robbe, Pauline, Oscier, David, Bailey, James, Rais, Syed, Bentley, Alison, Cawkwell, Lynn, Evans, Paul, Hillmen, Peter, Pratt, Guy, Allsup, David J., and Allan, James M.
Published: 2021
Full Text: View/download PDF

14. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Author: Milne, Paul, Wilhelm-Benartzi, Charlotte, Grunwald, Michael R., Bigley, Venetia, Dillon, Richard, Freeman, Sylvie D., Gallagher, Kathleen, Publicover, Amy, Pagan, Sarah, Marr, Helen, Jones, Gail L., Dickinson, Anne M., Grech, Angela, Burnett, Alan K., Russell, Nigel H., Levis, Mark, Knapper, Steven, and Collin, Matthew
Published: 2019
Full Text: View/download PDF

15. RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia.

Author: Aptullahoglu, Erhan, Nakjang, Sirintra, Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Willmore, Elaine, and Lunec, John
Subjects: DNA repair, CHRONIC lymphocytic leukemia, GENE expression, HEMATOLOGIC malignancies, OLDER people
Abstract: Chronic lymphocytic leukemia (CLL) is a genetically and clinically diverse hematological cancer affecting middle-aged and elderly individuals. Novel targeted therapy options are needed for patients who relapse following initial responses or who are intrinsically resistant to current treatments. There is a growing body of investigation currently underway on MDM2 inhibitors in clinical trials, reflecting the increasing interest in including these drugs in cancer treatment regimens. One of the developed compounds, idasanutlin (RG7388), has shown promise in early-stage clinical trials. It is a second-generation MDM2–p53-binding antagonist with enhanced potency, selectivity, and bioavailability. In addition to the TP53 status, which is an important determinant of the response, we have shown in our previous studies that the SF3B1 mutational status is also an independent predictive biomarker of the ex vivo CLL patient sample treatment response to RG7388. The objective of this study was to identify novel biomarkers associated with resistance to RG7388. Gene set enrichment analysis of differentially expressed genes (DEGs) between RG7388-sensitive and -resistant CLL samples showed that the increased p53 activity led to upregulation of pro-apoptosis pathway genes while DNA damage response pathway genes were additionally upregulated in resistant samples. Furthermore, differential expression of certain genes was detected, which could serve as the backbone for novel combination treatment approaches. This research provides preclinical data to guide the exploration of drug combination strategies with MDM2 inhibitors, leading to future clinical trials and associated biomarkers that may improve outcomes for CLL patients. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

16. Ibrutinib as first line therapy for mantle cell lymphoma: A multicentre, real-world UK study

Author: Tivey, Ann, primary, Shotton, Rohan, additional, Eyre, Toby A., additional, Lewis, David, additional, Stanton, Louise, additional, Allchin, Rebecca, additional, Walter, Harriet Sarah, additional, Miall, Fiona, additional, Zhao, Rui, additional, Santarsieri, Anna, additional, McCulloch, Rory, additional, Bishton, Mark, additional, Beech, Amy, additional, Willimott, Victoria Clare, additional, Fowler, Nicole, additional, Bedford, Claudia, additional, Goddard, Jack, additional, Protheroe, Samuel, additional, Everden, Angharad, additional, Tucker, David L, additional, Wright, Joshua, additional, Dukka, Srivasavi, additional, Thomson, Miriam, additional, Paneesha, Shankara, additional, Prahladan, Mahesh, additional, Hodson, Andrew, additional, Qureshi, Iman, additional, Koppana, Manasvi, additional, Owen, Mary, additional, Ediriwickrema, Kushani, additional, Marr, Helen, additional, Wilson, Jamie, additional, Lambert, Jonathan, additional, Wrench, David J, additional, Burney, Claire N, additional, Knott, Chloe, additional, Talbot, Georgina, additional, Gibb, Adam, additional, Lord, Angela, additional, Jackson, Barry, additional, Stern, Simon, additional, Sutton, Taylor, additional, Webb, Amy Caitlin, additional, Wilson, Marketa, additional, Thomas, Nicky, additional, Norman, Jane, additional, Davies, Elizabeth, additional, Lowry, Lisa, additional, Maddox, Jamie, additional, Phillips, Neil, additional, Crosbie, Nicola, additional, Flont, Marcin, additional, Nga, Emma LM, additional, Virchis, Andres, additional, Guerrero Camacho, Raisa, additional, Swe, Wunna, additional, Pillai, Arvind Radhakrishna, additional, Rees, Clare, additional, Bailey, James, additional, Jones, Steve Gareth, additional, Smith, Susan, additional, Sharpley, Faye, additional, Hildyard, Catherine, additional, Mohamedbhai, Sajir, additional, Nicholson, Toby, additional, Moule, Simon, additional, Chaturvedi, Anshuman, additional, and Linton, Kim, additional
Published: 2023
Full Text: View/download PDF

17. Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Author: Fordham, Sarah E., Blair, Helen J., Elstob, Claire J., Plummer, Ruth, Drew, Yvette, Curtin, Nicola J., Heidenreich, Olaf, Pal, Deepali, Jamieson, David, Park, Catherine, Pollard, John, Fields, Scott, Milne, Paul, Jackson, Graham H., Marr, Helen J., Menne, Tobias, Jones, Gail L., and Allan, James M.
Published: 2018
Full Text: View/download PDF

18. P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY

Author: Shotton, Rohan, primary, Tivey, Ann, additional, Eyre, Toby A., additional, Lewis, David, additional, Allchin, Rebecca, additional, Walter, Harriet, additional, Miall, Fiona, additional, Zhao, Rui, additional, Santarsieri, Anna, additional, Mcculloch, Rory, additional, Bishton, Mark, additional, Willimott, Victoria, additional, Fowler, Nicole, additional, Bedford, Claudia, additional, Goddard, Jack, additional, Protheroe, Samuel, additional, Prahladan, Mahesh, additional, Reeve, Miriam, additional, Paneesha, Shankara, additional, Marr, Helen, additional, Wilson, Jamie, additional, Ediriwickrema, Kushani, additional, Knott, Chloe, additional, Wrench, David, additional, Talbot, Georgina, additional, and Linton, Kim, additional
Published: 2023
Full Text: View/download PDF

19. SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia

Author: Aptullahoglu, Erhan, primary, Wallis, Jonathan P., additional, Marr, Helen, additional, Marshall, Scott, additional, Bown, Nick, additional, Willmore, Elaine, additional, and Lunec, John, additional
Published: 2023
Full Text: View/download PDF

20. Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.

Author: Stölzel, Friedrich, Stölzel, Friedrich, Fordham, Sarah E, Nandana, Devi, Lin, Wei-Yu, Blair, Helen, Elstob, Claire, Bell, Hayden L, Mohr, Brigitte, Ruhnke, Leo, Kunadt, Desiree, Dill, Claudia, Allsop, Daniel, Piddock, Rachel, Soura, Emmanouela-Niki, Park, Catherine, Fadly, Mohd, Rahman, Thahira, Alharbi, Abrar, Wobus, Manja, Altmann, Heidi, Röllig, Christoph, Wagenführ, Lisa, Jones, Gail L, Menne, Tobias, Jackson, Graham H, Marr, Helen J, Fitzgibbon, Jude, Onel, Kenan, Meggendorfer, Manja, Robinson, Amber, Bziuk, Zuzanna, Bowes, Emily, Heidenreich, Olaf, Haferlach, Torsten, Villar, Sara, Ariceta, Beñat, Diaz, Rosa Ayala, Altschuler, Steven J, Wu, Lani F, Prosper, Felipe, Montesinos, Pau, Martinez-Lopez, Joaquin, Bornhäuser, Martin, Allan, James M, Stölzel, Friedrich, Stölzel, Friedrich, Fordham, Sarah E, Nandana, Devi, Lin, Wei-Yu, Blair, Helen, Elstob, Claire, Bell, Hayden L, Mohr, Brigitte, Ruhnke, Leo, Kunadt, Desiree, Dill, Claudia, Allsop, Daniel, Piddock, Rachel, Soura, Emmanouela-Niki, Park, Catherine, Fadly, Mohd, Rahman, Thahira, Alharbi, Abrar, Wobus, Manja, Altmann, Heidi, Röllig, Christoph, Wagenführ, Lisa, Jones, Gail L, Menne, Tobias, Jackson, Graham H, Marr, Helen J, Fitzgibbon, Jude, Onel, Kenan, Meggendorfer, Manja, Robinson, Amber, Bziuk, Zuzanna, Bowes, Emily, Heidenreich, Olaf, Haferlach, Torsten, Villar, Sara, Ariceta, Beñat, Diaz, Rosa Ayala, Altschuler, Steven J, Wu, Lani F, Prosper, Felipe, Montesinos, Pau, Martinez-Lopez, Joaquin, Bornhäuser, Martin, and Allan, James M
Abstract: Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations in an elderly patient with acute myeloid leukemia (AML) that was chemoresistant to anthracycline and cytarabine but acutely sensitive to 5'-azacitidine (5'-Aza) hypomethylating monotherapy, resulting in long-term morphological remission. Given the role of TET2 as a regulator of genomic methylation, we hypothesized that mutant TET2 allele dosage affects response to 5'-Aza. Using an isogenic cell model system and an orthotopic mouse xenograft, we demonstrate that biallelic TET2 mutations confer sensitivity to 5'-Aza compared with cells with monoallelic mutations. Our data argue in favor of using hypomethylating agents for chemoresistant disease or as first-line therapy in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of precision medicine for patients with cancer.
Published: 2023

21. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition

Author: Aptullahoglu, Erhan, primary, Ciardullo, Carmela, additional, Wallis, Jonathan P., additional, Marr, Helen, additional, Marshall, Scott, additional, Bown, Nick, additional, Willmore, Elaine, additional, and Lunec, John, additional
Published: 2023
Full Text: View/download PDF

22. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

Author: Stölzel, Friedrich, primary, Fordham, Sarah E., additional, Nandana, Devi, additional, Lin, Wei-Yu, additional, Blair, Helen, additional, Elstob, Claire, additional, Bell, Hayden L., additional, Mohr, Brigitte, additional, Ruhnke, Leo, additional, Kunadt, Desiree, additional, Dill, Claudia, additional, Allsop, Daniel, additional, Piddock, Rachel, additional, Soura, Emmanouela-Niki, additional, Park, Catherine, additional, Fadly, Mohd, additional, Rahman, Thahira, additional, Alharbi, Abrar, additional, Wobus, Manja, additional, Altmann, Heidi, additional, Röllig, Christoph, additional, Wagenführ, Lisa, additional, Jones, Gail L., additional, Menne, Tobias, additional, Jackson, Graham H., additional, Marr, Helen J., additional, Fitzgibbon, Jude, additional, Onel, Kenan, additional, Meggendorfer, Manja, additional, Robinson, Amber, additional, Bziuk, Zuzanna, additional, Bowes, Emily, additional, Heidenreich, Olaf, additional, Haferlach, Torsten, additional, Villar, Sara, additional, Ariceta, Beñat, additional, Diaz, Rosa Ayala, additional, Altschuler, Steven J., additional, Wu, Lani F., additional, Prosper, Felipe, additional, Montesinos, Pau, additional, Martinez-Lopez, Joaquin, additional, Bornhäuser, Martin, additional, and Allan, James M., additional
Published: 2023
Full Text: View/download PDF

23. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)

Author: Lin, Wei-Yu, Fordham, Sarah E., Hungate, Eric, Sunter, Nicola J., Elstob, Claire, Xu, Yaobo, Park, Catherine, Quante, Anne, Strauch, Konstantin, Gieger, Christian, Skol, Andrew, Rahman, Thahira, Sucheston-Campbell, Lara, Wang, Junke, Hahn, Theresa, Clay-Gilmour, Alyssa I., Jones, Gail L., Marr, Helen J., Jackson, Graham H., Menne, Tobias, Collin, Mathew, Ivey, Adam, Hills, Robert K., Burnett, Alan K., Russell, Nigel H., Fitzgibbon, Jude, Larson, Richard A., Le Beau, Michelle M., Stock, Wendy, Heidenreich, Olaf, Alharbi, Abrar, Allsup, David J., Houlston, Richard S., Norden, Jean, Dickinson, Anne M., Douglas, Elisabeth, Lendrem, Clare, Daly, Ann K., Palm, Louise, Piechocki, Kim, Jeffries, Sally, Bornhauser, Martin, Rollig, Christoph, Altmann, Heidi, Ruhnke, Leo, Kunadt, Desiree, Wagenfuhr, Lisa, Cordell, Heather J., Darlay, Rebecca, Andersen, Mette K., Fontana, Maria C., Martinelli, Giovanni, Marconi, Giovanni, Sanz, Miguel A., Cervera, Jose, Gomez-Segui, Ines, Cluzeau, Thomas, Moreilhon, Chimene, Raynaud, Sophie, Sill, Heinz, Voso, Maria Teresa, Lo-Coco, Francesco, Dombret, Herve, Cheok, Meyling, Preudhomme, Claude, Gale, Rosemary E., Linch, David, Gaal-Wesinger, Julia, Masszi, Andras, Nowak, Daniel, Hofmann, Wolf-Karsten, Gilkes, Amanda, Porkka, Kimmo, Milosevic Feenstra, Jelena D., Kralovics, Robert, Grimwade, David, Meggendorfer, Manja, Haferlach, Torsten, Krizsan, Szilvia, Bodor, Csaba, Stolzel, Friedrich, Onel, Kenan, and Allan, James M.
Published: 2022

24. Persistent SARS-CoV-2 Infection in Patients With Secondary Antibody Deficiency: Successful Clearance Following Combination Casirivimab and Imdevimab (REGN-COV2) Monoclonal Antibody Therapy

Author: Taha, Yusri, primary, Wardle, Hayley, additional, Evans, Adam B., additional, Hunter, Ewan R., additional, Marr, Helen, additional, Osborne, Wendy, additional, Bashton, Matthew, additional, Smith, Darren, additional, Burton-Fanning, Shirelle, additional, Schmid, Matthias L., additional, and Duncan, Christopher J A, additional
Published: 2021
Full Text: View/download PDF

25. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author: Lin, Wei-Yu, primary, Fordham, Sarah E, additional, Hungate, Eric, additional, Sunter, Nicola J, additional, Elstob, Claire, additional, Xu, Yaobo, additional, Park, Catherine, additional, Quante, Anne, additional, Strauch, Konstantin, additional, Gieger, Christian, additional, Skol, Andrew, additional, Rahman, Thahira, additional, Sucheston-Campbell, Lara, additional, Wang, Junke, additional, Hahn, Theresa, additional, Clay-Gilmour, Alyssa I, additional, Jones, Gail L, additional, Marr, Helen J, additional, Jackson, Graham H, additional, Menne, Tobias, additional, Collin, Mathew, additional, Ivey, Adam, additional, Hills, Robert K, additional, Burnett, Alan K, additional, Russell, Nigel H, additional, Fitzgibbon, Jude, additional, Larson, Richard A, additional, Le Beau, Michelle M, additional, Stock, Wendy, additional, Heidenreich, Olaf, additional, Alharbi, Abrar, additional, Allsup, David J, additional, Houlston, Richard S, additional, Norden, Jean, additional, Dickinson, Anne M, additional, Douglas, Elisabeth, additional, Lendrem, Clare, additional, Daly, Ann K, additional, Palm, Louise, additional, Piechocki, Kim, additional, Jeffries, Sally, additional, Bornhäuser, Martin, additional, Röllig, Christoph, additional, Altmann, Heidi, additional, Ruhnke, Leo, additional, Kunadt, Desiree, additional, Wagenführ, Lisa, additional, Cordell, Heather J, additional, Darlay, Rebecca, additional, Andersen, Mette K, additional, Fontana, Maria C, additional, Martinelli, Giovanni, additional, Marconi, Giovani, additional, Sanz, Miguel A, additional, Cervera, José, additional, Gómez-Seguí, Inés, additional, Cluzeau, Thomas, additional, Moreilhon, Chimène, additional, Raynaud, Sophie, additional, Sill, Heinz, additional, Voso, Maria Teresa, additional, Lo-Coco, Francesco, additional, Dombret, Hervé, additional, Cheok, Meyling, additional, Preudhomme, Claude, additional, Gale, Rosemary E, additional, Linch, David, additional, Gaal-Wesinger, Julia, additional, Masszi, Andras, additional, Nowak, Daniel, additional, Hofmann, Wolf-Karsten, additional, Gilkes, Amanda, additional, Porkka, Kimmo, additional, Milosevic Feenstra, Jelena D, additional, Kralovics, Robert, additional, Grimwade, David, additional, Meggendorfer, Manja, additional, Haferlach, Torsten, additional, Krizsán, Szilvia, additional, Bödör, Csaba, additional, Stölzel, Friedrich, additional, Onel, Kenan, additional, and Allan, James M, additional
Published: 2021
Full Text: View/download PDF

26. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia

Author: Stölzel, Friedrich, primary, Fordham, Sarah E., additional, Lin, Wei-Yu, additional, Blair, Helen, additional, Elstob, Claire, additional, Nandana, Devi, additional, Mohr, Brigitte, additional, Ruhnke, Leo, additional, Kunadt, Desiree, additional, Dill, Claudia, additional, Allsop, Daniel, additional, Piddock, Rachel, additional, Soura, Emmanouela-Niki, additional, Park, Catherine, additional, Fadly, Mohd, additional, Rahman, Thahira, additional, Alharbi, Abrar, additional, Wobus, Manja, additional, Altmann, Heidi, additional, Röllig, Christoph, additional, Wagenführ, Lisa, additional, Jones, Gail L., additional, Menne, Tobias, additional, Jackson, Graham H., additional, Marr, Helen J., additional, Fitzgibbon, Jude, additional, Onel, Kenan, additional, Meggendorfer, Manja, additional, Heidenreich, Olaf, additional, Haferlach, Torsten, additional, Villar, Sara, additional, Ariceta, Beñat, additional, Diaz, Rosa Ayala, additional, Prosper, Felipe, additional, Montesinos, Pau, additional, Martinez-Lopez, Joaquin, additional, Bornhäuser, Martin, additional, and Allan, James M., additional
Published: 2021
Full Text: View/download PDF

27. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis

Author: Rampotas, Alexandros, primary, Wilson, Matthew R., additional, Lomas, Oliver, additional, Denny, Nicholas, additional, Leary, Heather, additional, Ferguson, Graeme, additional, McKay, Pamela, additional, Ebsworth, Tim, additional, Miller, Jonathan, additional, Shah, Nimish, additional, Martinez‐Calle, Nicolas, additional, Bishton, Mark, additional, Everden, Angharad, additional, Tucker, David, additional, El‐Hassad, Ezzat, additional, Hennessy, Brian, additional, Doherty, Dearbhla, additional, Prideaux, Steve, additional, Faryal, Rehman, additional, Hayat, Amjad, additional, Keohane, Clodagh, additional, Marr, Helen, additional, Gibb, Adam, additional, Pocock, Rachael, additional, Lambert, Jonathan, additional, Lacey, Rachel, additional, Elmusharaf, Nagah, additional, Clifford, Ruth, additional, and Eyre, Toby A., additional
Published: 2021
Full Text: View/download PDF

28. Myeloproliferative disorders in older people

Author: Osborne, Wendy, Jones, Gail L, Jackson, Graham H, and Marr, Helen
Published: 2012

29. Diagnosis and management of haematological malignancies in older people

Author: Marr, Helen, Jones, Gail L, Jackson, Graham H, and Osborne, Wendy
Published: 2011

30. Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia

Author: Barrow, Timothy M., primary, Nakjang, Sirintra, additional, Lafta, Fadhel, additional, Bilotkach, Kateryna, additional, Woodhouse, Laura, additional, Junge, Gesa, additional, Tudhope, Susan J., additional, Wallis, Jonathan P., additional, Marr, Helen, additional, Marshall, Scott, additional, Bown, Nick, additional, Willmore, Elaine, additional, and Strathdee, Gordon, additional
Published: 2020
Full Text: View/download PDF

31. The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets

Author: Marr, Helen E., Davey, Philip T., Boyle, Elizabeth A., and Blower, Peter R.
Published: 1994
Full Text: View/download PDF

32. Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.

Author: Eyre, Toby A., Riches, John C., Patten, Piers E. M., Walewska, Renata, Marr, Helen, Follows, George, Hillmen, Peter, and Schuh, Anna H.
Subjects: CHRONIC leukemia, RICHTER syndrome, LYMPHOCYTIC leukemia, HEMATOLOGY, DIFFUSE large B-cell lymphomas, CHRONIC lymphocytic leukemia
Abstract: RT occurs in 2-10% of CLL patients, usually during the disease course rather than at presentation, representing a transformation rate of 0-5-1% per CLL patient per year.2-5 RT should be suspected when a CLL patient develops one or more new "B symptoms", asymmetric, rapidly progressive lymphadenopathy, or a sudden lactate dehydrogenase (LDH) rise. Treatment approach Patients with RT commonly present in the context of pre-treated CLL and immunosuppression, and given the typical demographics of the CLL population, patients are often older with co-existing comorbidities.22 Treatment has historically involved multi-agent cytotoxic chemotherapy, more recently in combination with an anti-CD20 monoclonal antibody. Patients with I TP53 i aberrations or those who develop RT having previously received CLL-directed treatment have a poor outcome with R-CHOP alone, although this remains the standard of care and provides at least initial disease control for most patients. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. [Extracted from the article]
Published: 2022
Full Text: View/download PDF

33. Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Author: Allsup, David, primary, Lin, Wei Yu, additional, Fordham, Sarah Elizabeth, additional, Sunter, Nicola, additional, Elstob, Claire, additional, Rahman, Thahira, additional, Willmore, Elaine, additional, Shepherd, Colin, additional, Strathdee, Gordon, additional, Barrow, Timothy, additional, Mainou-Fowler, Tryfonia, additional, Piddock, Rachel, additional, Marr, Helen, additional, Wallis, Jonathan, additional, Marshall, Scott R., additional, Summerfield, Geoffery, additional, Pettitt, Andrew, additional, Pepper, Chris, additional, Fegan, Christopher, additional, Forconi, Francesco, additional, Dyer, Martin J.S., additional, Jayne, Sandrine, additional, Sellors, April, additional, Schuh, Anna, additional, Robbe, Pauline, additional, Oscier, David, additional, Houlston, Richard S., additional, Bailey, James, additional, Rais, Syed Ashar, additional, Bentley, Alison, additional, Cawkwell, Lynn, additional, Hillmen, Peter, additional, Pratt, Guy, additional, and Allan, James M., additional
Published: 2019
Full Text: View/download PDF

34. Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Author: Stoelzel, Friedrich, primary, Fordham, Sarah Elizabeth, primary, Lin, Wei Yu, primary, Blair, Helen, primary, Ruhnke, Leo, primary, Kunadt, Desireé, primary, Mohr, Brigitte, primary, Elstob, Claire, primary, Allsop, Daniel, primary, Nandana, Devi, primary, Soura, Emmanouela-Niki, primary, Park, Catherine, primary, Fadly, Mohd, primary, Rahman, Thahira, primary, Heidenreich, Olaf, primary, Altmann, Heidi, primary, Jones, Gail, primary, Menne, Tobias, primary, Wobus, Manja, primary, Jackson, Graham, primary, Marr, Helen, primary, Onel, Kenan, primary, Meggendorfer, Manja, primary, Haferlach, Torsten, primary, Bornhäuser, Martin, primary, and Allan, James M., primary
Published: 2019
Full Text: View/download PDF

35. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells

Author: Ciardullo, Carmela, primary, Aptullahoglu, Erhan, additional, Woodhouse, Laura, additional, Lin, Wei-Yu, additional, Wallis, Jonathan P, additional, Marr, Helen, additional, Marshall, Scott, additional, Bown, Nick, additional, Willmore, Elaine, additional, and Lunec, John, additional
Published: 2019
Full Text: View/download PDF

36. Serum Flt3 ligand is biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Author: Milne, Paul, primary, Wilhelm-Benartzi, Charlotte, additional, Grunwald, Michael R., additional, Bigley, Venetia, additional, Publicover, Amy, additional, Pagan, Sarah, additional, Marr, Helen, additional, Jones, Gail, additional, Dickinson, Anne, additional, Grech, Angela, additional, Burnett, Alan, additional, Russell, Nigel, additional, Levis, Mark, additional, Knapper, Steven, additional, and Collin, Matthew, additional
Published: 2019
Full Text: View/download PDF

37. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia

Author: Law, Philip J, Berndt, Sonja I, Speedy, Helen E, Camp, Nicola J, Sava, Georgina P, Skibola, Christine F, Holroyd, Amy, Joseph, Vijai, Sunter, Nicola J, Nieters, Alexandra, Bea, Silvia, Monnereau, Alain, Martin-Garcia, David, Goldin, Lynn R, Clot, Guillem, Teras, Lauren R, Quintela, Inés, Birmann, Brenda M, Jayne, Sandrine, Cozen, Wendy, Majid, Aneela, Smedby, Karin E, Lan, Qing, Dearden, Claire, Brooks-Wilson, Angela R., Hall, Andrew G, Purdue, Mark P, Mainou-Fowler, Tryfonia, Vajdic, Claire M, Jackson, Graham H, Cocco, Pierluigi, Marr, Helen, Zhang, Yawei, Zheng, Tongzhang, Giles, Graham G, Lawrence, Charles, Call, Timothy G, Liebow, Mark, Melbye, Mads, Glimelius, Bengt, Mansouri, Larry, Glenn, Martha, Curtin, Karen, Diver, W Ryan, Link, Brian K, Conde, Lucia, Bracci, Paige M., Holly, Elizabeth A, Jackson, Rebecca D, Tinker, Lesley F, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Maynadie, Marc, McKay, James, Albanes, Demetrius, Weinstein, Stephanie, Wang, Zhaoming, Caporaso, Neil E., Morton, Lindsay M, Severson, Richard K, Riboli, Elio, Vineis, Paolo, Vermeulen, Roel C H, Southey, Melissa C, Milne, Roger L., Clavel, Jacqueline, Topka, Sabine, Spinelli, John J, Kraft, Peter, Ennas, Maria Grazia, Summerfield, Geoffrey, Ferri, Giovanni M, Harris, Robert J, Miligi, Lucia, Pettitt, Andrew R, North, Kari E, Allsup, David J, Fraumeni, Joseph F, Bailey, James R, Offit, Kenneth, Pratt, Guy, Hjalgrim, Henrik, Pepper, Christopher, Chanock, Stephen J, Fegan, Chris, Rosenquist, Richard, de Sanjose, Silvia, Carracedo, Angel, Dyer, Martin J S, Catovsky, Daniel, Campo, Elias, Cerhan, James R., Allan, James M, Rothman, Nathanial, Houlston, Richard, Slager, Susan, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), Microsoft Research [Redmond], Microsoft Corporation [Redmond, Wash.], Department of Physics, Loyola College, Nungambakkam, Chennai – 600 034, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Aleppo [Aleppo], Sea Mammal Research Unit [University of St Andrews] (SMRU), School of Biology [University of St Andrews], University of St Andrews [Scotland]-University of St Andrews [Scotland]-Natural Environment Research Council (NERC), Department of Chemical Engineering, Imperial College London, De la Molécule aux Nanos-objets : Réactivité, Interactions et Spectroscopies (MONARIS), Institut de Chimie du CNRS (INC)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), The Cancer Council Victoria, University of Oulu, Uppsala Universitet [Uppsala], Université Paris Nanterre (UPN), University of Iowa [Iowa City], Registre des hémopathies malignes de Côte d'Or, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), B.B. Brodie Department of Neuroscience, Pennsylvania State University (Penn State), Penn State System, University of Newcastle [Australia] (UoN), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Department of Haematology, School of Medicine, Cardiff University, CIBER de Enfermedades Raras (CIBERER), University of Leeds, Haemato-oncology, Institute of cancer research, Mayo Clinic [Rochester], Northern Institute for Cancer Research [Newcastle] (NICR), Newcastle University [Newcastle], Institute of Cancer Research, Belmont, Sutton, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Sea Mammal Research Unit, Scottish Oceans Institute, University of St Andrews [Scotland], Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), University of Cardiff, Équipe Instrumentation embarquée et systèmes de surveillance intelligents (LAAS-S4M), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J), University of Newcastle [Callaghan, Australia] (UoN), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-2, Université Toulouse 1 Capitole (UT1)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse 1 Capitole (UT1)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), and Université Fédérale Toulouse Midi-Pyrénées
Subjects: Adult, Male, RM, Cancer och onkologi, B-Lymphocytes, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], Science, Chromosome Mapping, Middle Aged, Leukemia, Lymphocytic, Chronic, B-Cell, Polymorphism, Single Nucleotide, Article, Young Adult, Cancer and Oncology, Case-Control Studies, Antibody Formation, Chromosomes, Human, Humans, Female, Genetic Predisposition to Disease, RC, Genome-Wide Association Study
Abstract: Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however, much of the heritable risk remains unidentified. Here we perform a meta-analysis of six genome-wide association studies, imputed using a merged reference panel of 1,000 Genomes and UK10K data, totalling 6,200 cases and 17,598 controls after replication. We identify nine risk loci at 1p36.11 (rs34676223, P=5.04 × 10−13), 1q42.13 (rs41271473, P=1.06 × 10−10), 4q24 (rs71597109, P=1.37 × 10−10), 4q35.1 (rs57214277, P=3.69 × 10−8), 6p21.31 (rs3800461, P=1.97 × 10−8), 11q23.2 (rs61904987, P=2.64 × 10−11), 18q21.1 (rs1036935, P=3.27 × 10−8), 19p13.3 (rs7254272, P=4.67 × 10−8) and 22q13.33 (rs140522, P=2.70 × 10−9). These new and established risk loci map to areas of active chromatin and show an over-representation of transcription factor binding for the key determinants of B-cell development and immune response., Chronic lymphocytic leukaemia has a hereditary component, much of which remains to be identified. Here, the authors perform a genome-wide association study and find new risk loci for the disease, which are associated with genes involved in immune function.
Published: 2017
Full Text: View/download PDF

38. Not walking or communicating -- is all well?

Author: Ganly, Peter, Saleem, Mohamed, Marr, Helen, Burt, Michael, Florkowski, Christopher, and Williamson, Adrienne
Published: 2008

39. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21

Author: Sinclair, Paul. B., primary, Blair, Helen H., additional, Ryan, Sarra L., additional, Buechler, Lars, additional, Cheng, Joanna, additional, Clayton, Jake, additional, Hanna, Rebecca, additional, Hollern, Shaun, additional, Hawking, Zoe, additional, Bashton, Matthew, additional, Schwab, Claire J., additional, Jones, Lisa, additional, Russell, Lisa J., additional, Marr, Helen, additional, Carey, Peter, additional, Halsey, Christina, additional, Heidenreich, Olaf, additional, Moorman, Anthony V., additional, and Harrison, Christine J., additional
Published: 2018
Full Text: View/download PDF

40. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCR inhibitor setting: a UK wide analysis.

Author: Eyre, Toby A., Kirkwood, Amy A., Gohill, Sat, Follows, George, Walewska, Renata, Walter, Harriet, Cross, Matthew, Forconi, Francesco, Shah, Nimish, Chasty, Richard, Hart, Alistair, Broom, Angus, Marr, Helen, Patten, Piers E. M., Dann, Andy, Arumainathan, Arvind, Munir, Tal, Shankara, Paneesha, Bloor, Adrian, and Johnston, Rosalynd
Subjects: B cell receptors, PROTEIN-tyrosine kinases, PROGRESSION-free survival
Abstract: Summary: Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi‐centre retrospective analysis of 105 R/R CLL patients who received venetoclax pre‐National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1–15). 48% had TP53 disruption. At ≥2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3‐kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no prior BTKi, and 10% received both. Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [CR]). The overall response rate was 85% (CR 23%) in BTKi‐exposed patients, 92% (CR 38%) in Pi3Ki‐exposed patients and 80% (CR 20%) in both (P = 0·59). With a median follow‐up of 15·6 months, 1‐year progression‐free survival was 65·0% and 1‐year overall survival was 75·1%. Dose reduction or temporary interruption did not result in an inferior progression‐free or discontinuation‐free survival. Risk of progression or death after stopping a prior BCRi for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2·01 P = 0·05). Venetoclax is active and well tolerated in R/R CLL post ≥1 BCRi. Reason(s) for stopping BCRi influences venetoclax outcomes. [ABSTRACT FROM AUTHOR]
Published: 2019
Full Text: View/download PDF

41. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia

Author: Law, Phillip J., Berndt, Sonja I., Speedy, Helen E., Camp, Nicola J., Sava, Georgina P., Skibola, Christine F., Holroyd, Amy, Joseph, Vijai, Sunter, Nicola J., Nieters, Alexandra, Bea, Silvia, Monnereau, Alain, Martin-Garcia, David, Goldin, Lynn R., Clot, Guillem, Teras, Lauren R., Quintela, Ines, Birmann, Brenda M., Jayne, Sandrine, Cozen, Wendy, Majid, Aneela, Smedby, Karin E., Lan, Qing, Dearden, Claire, Brooks-Wilson, Angela R., Hall, Andrew G., Purdue, Mark P., Mainou-Fowler, Tryfonia, Vajdic, Claire M., Jackson, Graham H., Cocco, Pierluigi, Marr, Helen, Zhang, Yawei, Zheng, Tongzhang, Giles, Graham G., Lawrence, Charles, Call, Timothy G., Liebow, Mark, Melbye, Mads, Glimelius, Bengt, Mansouri, Larry, Glenn, Martha, Curtin, Karen, Diver, W. Ryan, Link, Brian K., Conde, Lucia, Bracci, Paige M., Holly, Elizabeth A., Jackson, Rebecca D., Tinker, Lesley F., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Maynadie, Marc, McKay, James, Albanes, Demetrius, Weinstein, Stephanie, Wang, Zhaoming, Caporaso, Neil E., Morton, Lindsay M., Severson, Richard K., Riboli, Elio, Vineis, Paolo, Vermeulen, Roel C. H., Southey, Melissa C., Milne, Roger L., Clavel, Jacqueline, Topka, Sabine, Spinelli, John J., Kraft, Peter, Ennas, Maria Grazia, Summerfield, Geoffrey, Ferri, Giovanni M., Harris, Robert J., Miligi, Lucia, Pettitt, Andrew R., North, Kari E., Allsup, David J., Fraumeni, Joseph F., Jr., Bailey, James R., Offit, Kenneth, Pratt, Guy, Hjalgrim, Henrik, Pepper, Chris, Chanock, Stephen J., Fegan, Chris, Rosenquist, Richard, de Sanjose, Silvia, Carracedo, Angel, Dyer, Martin J. S., Catovsky, Daniel, Campo, Elias, Cerhan, James R., Allan, James M., Rothman, Nathanial, Houlston, Richard, Slager, Susan L., Law, Phillip J., Berndt, Sonja I., Speedy, Helen E., Camp, Nicola J., Sava, Georgina P., Skibola, Christine F., Holroyd, Amy, Joseph, Vijai, Sunter, Nicola J., Nieters, Alexandra, Bea, Silvia, Monnereau, Alain, Martin-Garcia, David, Goldin, Lynn R., Clot, Guillem, Teras, Lauren R., Quintela, Ines, Birmann, Brenda M., Jayne, Sandrine, Cozen, Wendy, Majid, Aneela, Smedby, Karin E., Lan, Qing, Dearden, Claire, Brooks-Wilson, Angela R., Hall, Andrew G., Purdue, Mark P., Mainou-Fowler, Tryfonia, Vajdic, Claire M., Jackson, Graham H., Cocco, Pierluigi, Marr, Helen, Zhang, Yawei, Zheng, Tongzhang, Giles, Graham G., Lawrence, Charles, Call, Timothy G., Liebow, Mark, Melbye, Mads, Glimelius, Bengt, Mansouri, Larry, Glenn, Martha, Curtin, Karen, Diver, W. Ryan, Link, Brian K., Conde, Lucia, Bracci, Paige M., Holly, Elizabeth A., Jackson, Rebecca D., Tinker, Lesley F., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Maynadie, Marc, McKay, James, Albanes, Demetrius, Weinstein, Stephanie, Wang, Zhaoming, Caporaso, Neil E., Morton, Lindsay M., Severson, Richard K., Riboli, Elio, Vineis, Paolo, Vermeulen, Roel C. H., Southey, Melissa C., Milne, Roger L., Clavel, Jacqueline, Topka, Sabine, Spinelli, John J., Kraft, Peter, Ennas, Maria Grazia, Summerfield, Geoffrey, Ferri, Giovanni M., Harris, Robert J., Miligi, Lucia, Pettitt, Andrew R., North, Kari E., Allsup, David J., Fraumeni, Joseph F., Jr., Bailey, James R., Offit, Kenneth, Pratt, Guy, Hjalgrim, Henrik, Pepper, Chris, Chanock, Stephen J., Fegan, Chris, Rosenquist, Richard, de Sanjose, Silvia, Carracedo, Angel, Dyer, Martin J. S., Catovsky, Daniel, Campo, Elias, Cerhan, James R., Allan, James M., Rothman, Nathanial, Houlston, Richard, and Slager, Susan L.
Abstract: Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however, much of the heritable risk remains unidentified. Here we perform a meta-analysis of six genome-wide association studies, imputed using a merged reference panel of 1,000 Genomes and UK10K data, totalling 6,200 cases and 17,598 controls after replication. We identify nine risk loci at 1p36.11 (rs34676223, P = 5.04 X 10 (-) (13)), 1q42.13 (rs41271473, P = 1.06 X 10 (-) (10)), 4q24 (rs71597109, P = 1.37 X 10 (-) (10)), 4q35.1 (rs57214277, P = 3.69 X 10 (-) (8)), 6p21.31 (rs3800461, P = 1.97 X 10 (-) (8)), 11q23.2 (rs61904987, P = 2.64 X 10 (-) (11)), 18q21.1 (rs1036935, P = 3.27 X 10 (-) (8)), 19p13.3 (rs7254272, P = 4.67 X 10 (-) (8)) and 22q13.33 (rs140522, P = 2.70 X 10 (-) (9)). These new and established risk loci map to areas of active chromatin and show an over-representation of transcription factor binding for the key determinants of B-cell development and immune response.
Published: 2017
Full Text: View/download PDF

42. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia

Author: LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-2, Law, Philip J, Berndt, Sonja I., Speedy, Helen E, Camp, Nicola J, Sava, Georgina P, Skibola, Christine F., Holroyd, Amy, Joseph, Vijai, Sunter, Nicola J, Nieters, Alexandra, Bea, Silvia, Monnereau, Alain, Martin-Garcia, David, Goldin, Lynn R, Clot, Guillem, Teras, Lauren R., Quintela, Inés, Birmann, Brenda M., Jayne, Sandrine, Cozen, Wendy, Majid, Aneela, Smedby, Karin E, Lan, Qing, Dearden, Claire, Brooks-Wilson, Angela R., Hall, Andrew G, Purdue, Mark P., Mainou-Fowler, Tryfonia, Vajdic, Claire M., Jackson, Graham H, Cocco, Pierluigi, Marr, Helen, Zhang, Yawei, Zheng, Tongzhang, Giles, Graham G., Lawrence, Charles, Call, Timothy G., Liebow, Mark, Melbye, Mads, Glimelius, Bengt, Mansouri, Larry, Glenn, Martha, Curtin, Karen, Diver, W. Ryan, Link, Brian K., Conde, Lucia, Bracci, Paige M., Holly, Elizabeth A., Jackson, Rebecca D., Tinker, Lesley F., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Maynadie, Marc, McKay, James, Albanes, Demetrius, Weinstein, Stephanie, Wang, Zhaoming, Caporaso, Neil E, Morton, Lindsay M., Severson, Richard K., Riboli, Elio, Vineis, Paolo, Vermeulen, Roel C H, Southey, Melissa C., Milne, Roger L, Clavel, Jacqueline, Topka, Sabine, Spinelli, John, Kraft, Peter, Ennas, Maria Grazia, Summerfield, Geoffrey, Ferri, Giovanni M, Harris, Robert J, Miligi, Lucia, Pettitt, Andrew R, North, Kari E., Allsup, David J, Fraumeni, Joseph F., Bailey, James R, Offit, Kenneth, Pratt, Guy, Hjalgrim, Henrik, Pepper, Chris, Chanock, Stephen J., Fegan, Chris, Rosenquist, Richard, De Sanjose, Silvia, Carracedo, Angel, Dyer, Martin J S, Catovsky, Daniel, Campo, Elias, Cerhan, James R., Allan, James M, Rothman, Nathanial, Houlston, Richard S, Slager, Susan L., LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-2, Law, Philip J, Berndt, Sonja I., Speedy, Helen E, Camp, Nicola J, Sava, Georgina P, Skibola, Christine F., Holroyd, Amy, Joseph, Vijai, Sunter, Nicola J, Nieters, Alexandra, Bea, Silvia, Monnereau, Alain, Martin-Garcia, David, Goldin, Lynn R, Clot, Guillem, Teras, Lauren R., Quintela, Inés, Birmann, Brenda M., Jayne, Sandrine, Cozen, Wendy, Majid, Aneela, Smedby, Karin E, Lan, Qing, Dearden, Claire, Brooks-Wilson, Angela R., Hall, Andrew G, Purdue, Mark P., Mainou-Fowler, Tryfonia, Vajdic, Claire M., Jackson, Graham H, Cocco, Pierluigi, Marr, Helen, Zhang, Yawei, Zheng, Tongzhang, Giles, Graham G., Lawrence, Charles, Call, Timothy G., Liebow, Mark, Melbye, Mads, Glimelius, Bengt, Mansouri, Larry, Glenn, Martha, Curtin, Karen, Diver, W. Ryan, Link, Brian K., Conde, Lucia, Bracci, Paige M., Holly, Elizabeth A., Jackson, Rebecca D., Tinker, Lesley F., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Maynadie, Marc, McKay, James, Albanes, Demetrius, Weinstein, Stephanie, Wang, Zhaoming, Caporaso, Neil E, Morton, Lindsay M., Severson, Richard K., Riboli, Elio, Vineis, Paolo, Vermeulen, Roel C H, Southey, Melissa C., Milne, Roger L, Clavel, Jacqueline, Topka, Sabine, Spinelli, John, Kraft, Peter, Ennas, Maria Grazia, Summerfield, Geoffrey, Ferri, Giovanni M, Harris, Robert J, Miligi, Lucia, Pettitt, Andrew R, North, Kari E., Allsup, David J, Fraumeni, Joseph F., Bailey, James R, Offit, Kenneth, Pratt, Guy, Hjalgrim, Henrik, Pepper, Chris, Chanock, Stephen J., Fegan, Chris, Rosenquist, Richard, De Sanjose, Silvia, Carracedo, Angel, Dyer, Martin J S, Catovsky, Daniel, Campo, Elias, Cerhan, James R., Allan, James M, Rothman, Nathanial, Houlston, Richard S, and Slager, Susan L.
Published: 2017

43. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia

Author: Law, Philip J., Berndt, Sonja I., Speedy, Helen E., Camp, Nicola J., Sava, Georgina P., Skibola, Christine F., Holroyd, Amy, Joseph, Vijai, Sunter, Nicola J., Nieters, Alexandra, Bea, Silvia, Monnereau, Alain, Martin-Garcia, David, Goldin, Lynn R., Clot, Guillem, Teras, Lauren R., Quintela, Inés, Birmann, Brenda M., Jayne, Sandrine, Cozen, Wendy, Majid, Aneela, Smedby, Karin E., Lan, Qing, Dearden, Claire, Brooks-Wilson, Angela R., Hall, Andrew G., Purdue, Mark P., Mainou-Fowler, Tryfonia, Vajdic, Claire M., Jackson, Graham H., Cocco, Pierluigi, Marr, Helen, Zhang, Yawei, Zheng, Tongzhang, Giles, Graham G., Lawrence, Charles, Call, Timothy G., Liebow, Mark, Melbye, Mads, Glimelius, Bengt, Mansouri, Larry, Glenn, Martha, Curtin, Karen, Diver, W. Ryan, Link, Brian K., Conde, Lucia, Bracci, Paige M., Holly, Elizabeth A., Jackson, Rebecca D., Tinker, Lesley F., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Maynadie, Marc, McKay, James, Albanes, Demetrius, Weinstein, Stephanie, Wang, Zhaoming, Caporaso, Neil E., Morton, Lindsay M., Severson, Richard K., Riboli, Elio, Vineis, Paolo, Vermeulen, Roel C.H., Southey, Melissa C., Milne, Roger L., Clavel, Jacqueline, Topka, Sabine, Spinelli, John J., Kraft, Peter, Ennas, Maria Grazia, Summerfield, Geoffrey, Ferri, Giovanni M., Harris, Robert J., Miligi, Lucia, Pettitt, Andrew R., North, Kari E., Allsup, David J., Fraumeni, Joseph F., Bailey, James R., Offit, Kenneth, Pratt, Guy, Hjalgrim, Henrik, Pepper, Chris, Chanock, Stephen J., Fegan, Chris, Rosenquist, Richard, De Sanjose, Silvia, Carracedo, Angel, Dyer, Martin J.S., Catovsky, Daniel, Campo, Elias, Cerhan, James R., Allan, James M., Rothman, Nathanial, Houlston, Richard, Slager, Susan, Law, Philip J., Berndt, Sonja I., Speedy, Helen E., Camp, Nicola J., Sava, Georgina P., Skibola, Christine F., Holroyd, Amy, Joseph, Vijai, Sunter, Nicola J., Nieters, Alexandra, Bea, Silvia, Monnereau, Alain, Martin-Garcia, David, Goldin, Lynn R., Clot, Guillem, Teras, Lauren R., Quintela, Inés, Birmann, Brenda M., Jayne, Sandrine, Cozen, Wendy, Majid, Aneela, Smedby, Karin E., Lan, Qing, Dearden, Claire, Brooks-Wilson, Angela R., Hall, Andrew G., Purdue, Mark P., Mainou-Fowler, Tryfonia, Vajdic, Claire M., Jackson, Graham H., Cocco, Pierluigi, Marr, Helen, Zhang, Yawei, Zheng, Tongzhang, Giles, Graham G., Lawrence, Charles, Call, Timothy G., Liebow, Mark, Melbye, Mads, Glimelius, Bengt, Mansouri, Larry, Glenn, Martha, Curtin, Karen, Diver, W. Ryan, Link, Brian K., Conde, Lucia, Bracci, Paige M., Holly, Elizabeth A., Jackson, Rebecca D., Tinker, Lesley F., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Maynadie, Marc, McKay, James, Albanes, Demetrius, Weinstein, Stephanie, Wang, Zhaoming, Caporaso, Neil E., Morton, Lindsay M., Severson, Richard K., Riboli, Elio, Vineis, Paolo, Vermeulen, Roel C.H., Southey, Melissa C., Milne, Roger L., Clavel, Jacqueline, Topka, Sabine, Spinelli, John J., Kraft, Peter, Ennas, Maria Grazia, Summerfield, Geoffrey, Ferri, Giovanni M., Harris, Robert J., Miligi, Lucia, Pettitt, Andrew R., North, Kari E., Allsup, David J., Fraumeni, Joseph F., Bailey, James R., Offit, Kenneth, Pratt, Guy, Hjalgrim, Henrik, Pepper, Chris, Chanock, Stephen J., Fegan, Chris, Rosenquist, Richard, De Sanjose, Silvia, Carracedo, Angel, Dyer, Martin J.S., Catovsky, Daniel, Campo, Elias, Cerhan, James R., Allan, James M., Rothman, Nathanial, Houlston, Richard, and Slager, Susan
Abstract: Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however, much of the heritable risk remains unidentified. Here we perform a meta-analysis of six genome-wide association studies, imputed using a merged reference panel of 1,000 Genomes and UK10K data, totalling 6,200 cases and 17,598 controls after replication. We identify nine risk loci at 1p36.11 (rs34676223, P=5.04 × 10-13), 1q42.13 (rs41271473, P=1.06 × 10-10), 4q24 (rs71597109, P=1.37 × 10 -10), 4q35.1 (rs57214277, P=3.69 × 10-8), 6p21.31 (rs3800461, P=1.97 × 10-8), 11q23.2 (rs61904987, P=2.64 × 10-11), 18q21.1 (rs1036935, P=3.27 × 10-8), 19p13.3 (rs7254272, P=4.67 × 10-8) and 22q13.33 (rs140522, P=2.70 × 10-9). These new and established risk loci map to areas of active chromatin and show an over-representation of transcription factor binding for the key determinants of B-cell development and immune response.
Published: 2017

44. The Role of HOXA4 in Chronic Lymphocytic Leukaemia Progression and Response to Therapy

Author: Barrow, Timothy M, primary, Woodhouse, Laura, additional, Junge, Gesa, additional, Tudhope, Susan J, additional, Behardien, Charlotte, additional, Wallis, Jonathan P, additional, Marr, Helen J, additional, Marshall, Scott R, additional, Bown, Nick, additional, Willmore, Elaine, additional, and Strathdee, Gordon, additional
Published: 2016
Full Text: View/download PDF

45. The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia

Author: Ciardullo, Carmela, primary, Woodhouse, Laura, additional, Aptullahoglu, Erhan, additional, Wallis, Jonathan P, additional, Marr, Helen J, additional, Marshall, Scott R, additional, Bown, Nick, additional, Willmore, Elaine, additional, and Lunec, John, additional
Published: 2016
Full Text: View/download PDF

46. Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Author: Fordham, Sarah E, primary, Blair, Helen J, additional, Elstob, Claire J, additional, Pal, Deepali, additional, Curtin, Nicola, additional, Milne, Paul, additional, Collin, Matthew, additional, Jackson, Graham H, additional, Marr, Helen J, additional, Heidenreich, Olaf, additional, Plummer, Ruth, additional, Pollard, John, additional, Menne, Tobias F., additional, Jones, Gail L, additional, and Allan, James M, additional
Published: 2016
Full Text: View/download PDF

47. Targeting Ikkα in CLL: Inhibition of Non-Canonical NF-κb Signaling Decreases Survival and Proliferation of CD40L-Stimulated Primary CLL Cells

Author: Willmore, Elaine, primary, Gardner, Aaron, additional, Tudhope, Susan J, additional, Herridge, Andrew, additional, Hunter, Jill, additional, Wallis, Jonathan P, additional, Marr, Helen J, additional, Berretta, Giacomo, additional, Breen, David, additional, Paul, Andrew, additional, Edwards, Darren, additional, Young, Louise C, additional, Suckling, Colin J, additional, Plevin, Robin, additional, Boyd, Marie, additional, Allan, James M, additional, Mackay, Simon, additional, and Perkins, Neil D, additional
Published: 2016
Full Text: View/download PDF

48. P B S-1086, a “Pan-Rel” Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells

Author: Tudhope, Susan J, primary, Mulligan, Evan A, additional, Hunter, Jill E, additional, Summerfield, Geoffrey P, additional, Marshall, Scott, additional, Wallis, Jonathan, additional, Marr, Helen, additional, Evans, Paul, additional, Lowe, Chris, additional, Durkacz, Barbara W, additional, Zhang, Jie, additional, Meshulam, Jeffrey, additional, Bobb, Kathryn, additional, and Willmore, Elaine, additional
Published: 2012
Full Text: View/download PDF

49. Searching for clarity in therapy-related myelodysplastic syndrome/acute myeloid leukemia prognostication

Author: Fordham, Sarah E., primary, Marr, Helen, additional, and Allan, James M., additional
Published: 2012
Full Text: View/download PDF

50. Successful Treatment of Transplant Associated Microangiopathy with Rituximab

Author: Ganly, Peter, primary, Marr, Helen, primary, McDonald, Emma-Jane, primary, Merriman, Eileen, primary, Mangos, Hilda, primary, Stoddart, Catherine, primary, and Smith, Mark, primary
Published: 2008
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

158 results on '"Marr, Helen"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources